TransMedics Group (TMDX) Projected to Post Quarterly Earnings on Thursday

TransMedics Group (NASDAQ:TMDX - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect TransMedics Group to post earnings of $0.29 per share and revenue of $123.39 million for the quarter.

TransMedics Group Trading Down 0.7 %

NASDAQ:TMDX traded down $0.68 during midday trading on Friday, hitting $93.50. 1,295,458 shares of the company traded hands, compared to its average volume of 1,353,822. The firm's fifty day moving average is $74.46 and its 200-day moving average is $77.42. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a market capitalization of $3.16 billion, a P/E ratio of 99.47 and a beta of 2.14. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

Analysts Set New Price Targets

A number of research firms have weighed in on TMDX. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Wednesday. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.